Skip to main content

Articles

Page 19 of 62

  1. It has been demonstrated that patients with type 2 diabetes mellitus (DM) is associated with increased cardiovascular risk. However, little is known regarding the long-term prognosis in diabetic patients who e...

    Authors: Hui-Wen Zhang, Jing-Lu Jin, Ye-Xuan Cao, Yuan-Lin Guo, Na-Qiong Wu, Cheng-Gang Zhu, Rui-Xia Xu, Qian Dong and Jian-Jun Li
    Citation: Cardiovascular Diabetology 2021 20:214
    Content type: Original investigation Published on:

  2. The treatment effects on hospitalization for heart failure (hHF) from sodium-glucose cotransporter 2 (SGLT2) inhibitors may vary among type 2 diabetes (T2D) patients depending on whether or not they have estab...

    Authors: Shih-Chieh Shao, Kai-Cheng Chang, Swu-Jane Lin, Shang-Hung Chang, Ming-Jui Hung, Yuk-Ying Chan and Edward Chia-Cheng Lai
    Citation: Cardiovascular Diabetology 2021 20:213
    Content type: Original investigation Published on:

  3. Left ventricular (LV) involvement in diabetic cardiomyopathy has been reported; however, only limited data exist on right ventricular (RV) involvement. Therefore, our purpose was to investigate RV systolic dys...

    Authors: Saki Todo, Hidekazu Tanaka, Yuki Yamauchi, Shun Yokota, Yasuhide Mochizuki, Hiroaki Shiraki, Kentaro Yamashita, Ayu Shono, Makiko Suzuki, Keiko Sumimoto, Yusuke Tanaka, Yushi Hirota, Wataru Ogawa and Ken-ichi Hirata
    Citation: Cardiovascular Diabetology 2021 20:212
    Content type: Original investigation Published on:

  4. Stress-induced hyperglycaemia at time of hospital admission has been linked to worse prognosis following acute myocardial infarction (AMI). In addition to glucose, other glucose-related indices, such as HbA1c,...

    Authors: Ching-Hui Sia, Mervyn Huan-Hao Chan, Huili Zheng, Junsuk Ko, Andrew Fu-Wah Ho, Jun Chong, David Foo, Ling-Li Foo, Patrick Zhan-Yun Lim, Boon Wah Liew, Ping Chai, Tiong-Cheng Yeo, Huay-Cheem Tan, Terrance Chua, Mark Yan-Yee Chan, Jack Wei Chieh Tan…
    Citation: Cardiovascular Diabetology 2021 20:211
    Content type: Original investigation Published on:

  5. Besides providing reassurance about cardiovascular (CV) safety of newer diabetes drugs, cardiovascular outcome trials (CVOTs) have also shown encouraging benefits on some CV endpoints. The contribution of the ...

    Authors: Maria Ida Maiorino, Miriam Longo, Lorenzo Scappaticcio, Giuseppe Bellastella, Paolo Chiodini, Katherine Esposito and Dario Giugliano
    Citation: Cardiovascular Diabetology 2021 20:210
    Content type: Review Published on:

  6. The combination of diabetes mellitus (DM) and chronic kidney disease (CKD) is associated with a high risk of mortality. Annual assessment of the estimated glomerular filtration rate (eGFR) is recommended for p...

    Authors: Yu-Shan Chang, Yu-Hsuan Li and I-Te Lee
    Citation: Cardiovascular Diabetology 2021 20:209
    Content type: Original investigation Published on:

  7. Advanced glycation end-products, indicated by skin autofluorescence (SAF) levels, could be prognostic predictors of all-cause and cardiovascular mortality in patients with diabetes mellitus (DM) and renal dise...

    Authors: Mitsuhiro Kunimoto, Miho Yokoyama, Kazunori Shimada, Tomomi Matsubara, Tatsuro Aikawa, Shohei Ouchi, Kosuke Fukao, Tetsuro Miyazaki, Kei Fujiwara, Abidan Abulimiti, Akio Honzawa, Akie Shimada, Taira Yamamoto, Atsushi Amano, Masakazu Saitoh, Tomoyuki Morisawa…
    Citation: Cardiovascular Diabetology 2021 20:208
    Content type: Original investigation Published on:

  8. Previous studies suggested an adverse association between higher fasting blood glucose (FBG) variability and cardiovascular disease (CVD). Lifetime risk provides an absolute risk assessment during the remainde...

    Authors: Jianing Bi, Lulu Song, Lulin Wang, Mingyang Wu, Shouhua Chen, Youjie Wang, Shouling Wu and Yaohua Tian
    Citation: Cardiovascular Diabetology 2021 20:207
    Content type: Original investigation Published on:

  9. Insulin resistance (IR) is a known risk factor for cardiovascular disease (CVD) in non-diabetic patients through the association of hyperglycemia or associated metabolic factors. The triglyceride glucose (TyG)...

    Authors: Ya-Wen Lu, Chun-Chin Chang, Ruey-Hsing Chou, Yi-Lin Tsai, Li-Kuo Liu, Liang-Kung Chen, Po-Hsun Huang and Shing-Jong Lin
    Citation: Cardiovascular Diabetology 2021 20:206
    Content type: Original investigation Published on:

  10. Cardiovascular disease (CVD) remains the leading cause of death in patients with type 2 diabetes (T2D). Older age, prior heart failure (HF) and CV events, peripheral artery disease, and kidney complications ca...

    Authors: Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, Giuseppe Bellastella and Katherine Esposito
    Citation: Cardiovascular Diabetology 2021 20:205
    Content type: Commentary Published on:

  11. With emerging evidence on the efficacy of adding dapagliflozin to standard care for patients with heart failure with reduced ejection fraction (HFrEF), this study assessed the cost-effectiveness of add-on dapa...

    Authors: Chia-Te Liao, Chun-Ting Yang, Han Siong Toh, Wei-Ting Chang, Hung-Yu Chang, Fang-Hsiu Kuo, Mei-Chuan Lee, Yi-Ming Hua, Hsin-Ju Tang, Carol Strong and Huang-Tz Ou
    Citation: Cardiovascular Diabetology 2021 20:204
    Content type: Original investigation Published on:

  12. To assess the effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) for type 2 diabetes on kidney outcomes stratified by patient baseline estimated glomerular filtration rate (eGFR) levels (i.e., eGFR...

    Authors: Fang-Ju Lin, Chi-Chuan Wang, Chien-Ning Hsu, Chen-Yi Yang, Chih-Yuan Wang and Huang-Tz Ou
    Citation: Cardiovascular Diabetology 2021 20:203
    Content type: Original investigation Published on:

  13. Insulin resistance contributes to the development of type 2 diabetes (T2D) and is also a cardiovascular risk factor. The aim of this study was to investigate the potential association between insulin resistanc...

    Authors: Alexander Zabala, Vladimer Darsalia, Marcus Lind, Ann-Marie Svensson, Stefan Franzén, Björn Eliasson, Cesare Patrone, Magnus Jonsson and Thomas Nyström
    Citation: Cardiovascular Diabetology 2021 20:202
    Content type: Original investigation Published on:

  14. Previous studies reported the prognostic value of the atherogenic index of plasma (AIP) in the course of atherosclerosis and other cardiovascular diseases (CVDs). Still, the predictive utility of the AIP is un...

    Authors: Liyao Fu, Ying Zhou, Jiaxing Sun, Zhaowei Zhu, Zhenhua Xing, Shenghua Zhou, Yongjun Wang and Shi Tai
    Citation: Cardiovascular Diabetology 2021 20:201
    Content type: Original investigation Published on:

  15. Sodium-glucose cotransporter 2 (SGLT2) inhibition reduces cardiovascular events in type 2 diabetes (T2DM) and is associated with a reduction in left ventricular (LV) mass index. However, the impact on right ve...

    Authors: Bradley Sarak, Subodh Verma, C. David Mazer, Hwee Teoh, Adrian Quan, Richard E. Gilbert, Shaun G. Goodman, Karan Bami, Otávio R. Coelho-Filho, Vineeta Ahooja, Djeven P. Deva, Vinay Garg, Sumeet Gandhi, Kim A. Connelly and Andrew T. Yan
    Citation: Cardiovascular Diabetology 2021 20:200
    Content type: Original investigation Published on:

  16. Empagliflozin is a selective sodium–glucose cotransporter 2 (SGLT2) inhibitor used to lower blood sugar in adults with type 2 diabetes. Empagliflozin also exerts cardioprotective effects independent from gluco...

    Authors: Zhaoyang Hu, Feng Ju, Lei Du and Geoffrey W. Abbott
    Citation: Cardiovascular Diabetology 2021 20:199
    Content type: Original investigation Published on:

  17. Patients with Covid-19 place new challenges on the management of type 2 diabetes, including the questions of whether glucose-lowering therapy should be adjusted during infection and how to manage a return to n...

    Authors: Leszek Czupryniak, Dror Dicker, Roger Lehmann, Martin Prázný and Guntram Schernthaner
    Citation: Cardiovascular Diabetology 2021 20:198
    Content type: Commentary Published on:

  18. Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic disease and independently affects the development of cardiovascular (CV) disease. We investigated whether hepatic steatosis and/...

    Authors: Jiyun Park, Gyuri Kim, Hasung Kim, Jungkuk Lee, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur and Jae Hyeon Kim
    Citation: Cardiovascular Diabetology 2021 20:197
    Content type: Original investigation Published on:

  19. The impressive results of recent clinical trials with glucagon-like peptide-1 receptor agonists (GLP-1Ra) and sodium glucose transporter 2 inhibitors (SGLT-2i) in terms of cardiovascular protection prompted a ...

    Authors: Andrea Natali, Lorenzo Nesti, Domenico Tricò and Ele Ferrannini
    Citation: Cardiovascular Diabetology 2021 20:196
    Content type: Review Published on:

  20. The risk of heart failure among diabetic individuals is high, even under tight glycemic control. The correlates and mediators of heart failure risk in individuals with diabetes need more elucidation in large p...

    Authors: Matti A. Vuori, Jaakko Reinikainen, Stefan Söderberg, Ellinor Bergdahl, Pekka Jousilahti, Hugh Tunstall-Pedoe, Tanja Zeller, Dirk Westermann, Susana Sans, Allan Linneberg, Licia Iacoviello, Simona Costanzo, Veikko Salomaa, Stefan Blankenberg, Kari Kuulasmaa and Teemu J. Niiranen
    Citation: Cardiovascular Diabetology 2021 20:195
    Content type: Original investigation Published on:

  21. The REWIND trial demonstrated cardiovascular (CV) benefits to patients with type 2 diabetes and multiple CV risk factors or established CV disease. This exploratory analysis evaluated the degree to which the e...

    Authors: Manige Konig, Matthew C. Riddle, Helen M. Colhoun, Kelley R. Branch, Charles M. Atisso, Mark C. Lakshmanan, Reema Mody, Sohini Raha and Hertzel C. Gerstein
    Citation: Cardiovascular Diabetology 2021 20:194
    Content type: Original investigation Published on:

  22. Liver stiffness measurement (LSM, which reflects fibrosis) and controlled attenuation parameter (CAP, which reflects steatosis), two parameters derived from hepatic transient elastography (TE), have scarcely b...

    Authors: Claudia R. L. Cardoso, Cristiane A. Villela-Nogueira, Nathalie C. Leite and Gil F. Salles
    Citation: Cardiovascular Diabetology 2021 20:193
    Content type: Original investigation Published on:

  23. The prognostic role of hyperglycemia in patients with myocardial infarction and obstructive coronary arteries (MIOCA) is acknowledged, while data on non-obstructive coronary arteries (MINOCA) are still lacking...

    Authors: Pasquale Paolisso, Alberto Foà, Luca Bergamaschi, Francesco Angeli, Michele Fabrizio, Francesco Donati, Sebastiano Toniolo, Chiara Chiti, Andrea Rinaldi, Andrea Stefanizzi, Matteo Armillotta, Angelo Sansonetti, Ilenia Magnani, Gianmarco Iannopollo, Paola Rucci, Gianni Casella…
    Citation: Cardiovascular Diabetology 2021 20:192
    Content type: Original investigation Published on:

  24. A prothrombotic state is a typical feature of type 2 diabetes mellitus (T2DM). Apart from increased platelet reactivity, endothelial dysfunction, hyperfibrinogenemia, and hypofibrinolysis are observed in T2DM....

    Authors: Agata Hanna Bryk-Wiązania and Anetta Undas
    Citation: Cardiovascular Diabetology 2021 20:191
    Content type: Review Published on:

  25. Insulin resistance (IR), evaluation of which is difficult and complex, is closely associated with cardiovascular disease. Recently, various IR surrogates have been proposed and proved to be highly correlated w...

    Authors: Qi Zhao, Yu-Jing Cheng, Ying-Kai Xu, Zi-Wei Zhao, Chi Liu, Tie-Nan Sun and Yu-Jie Zhou
    Citation: Cardiovascular Diabetology 2021 20:190
    Content type: Original investigation Published on:

  26. A meta-analysis is presented of cardiovascular outcome trials (CVOTs) comparing glucagon-like peptide-1 receptor agonists (GLP-1RA) versus placebo on cardiorenal outcomes in patients with type 2 diabetes melli...

    Authors: Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, Paola Caruso, Maria Ida Maiorino, Giuseppe Bellastella, Antonio Ceriello, Paolo Chiodini and Katherine Esposito
    Citation: Cardiovascular Diabetology 2021 20:189
    Content type: Original investigation Published on:

  27. Apolipoprotein (Apo) A1 and Apo B are strongly associated with the risk of atherosclerotic cardiovascular disease (ASCVD). However, the relationship between the Apo B/A1 ratio and the morphology of coronary vu...

    Authors: Fuxue Deng, Danni Li, Lei Lei, Qiang Yang, Qing Li, Hongtao Wang, Jie Deng, Qiangsun Zheng and Wei Jiang
    Citation: Cardiovascular Diabetology 2021 20:188
    Content type: Original investigation Published on:

  28. Patients with type 2 diabetes (T2D) may experience frequent body weight changes over time. The prognostic impact of these weight changes (gains or losses) requires further study.

    Authors: João Pedro Ferreira, Patrick Rossignol, George Bakris, Cyrus Mehta, William B. White and Faiez Zannad
    Citation: Cardiovascular Diabetology 2021 20:187
    Content type: Original investigation Published on:

  29. Identification of the effective subtypes of treatment for heart failure (HF) is an essential topic for optimizing treatment of the disorder. We hypothesized that the beneficial effect of SGLT2 inhibitors (SGLT...

    Authors: Kenya Kusunose, Takumi Imai, Atsushi Tanaka, Kaoru Dohi, Kazuki Shiina, Takahisa Yamada, Keisuke Kida, Kazuo Eguchi, Hiroki Teragawa, Yasuchika Takeishi, Nobuyuki Ohte, Hirotsugu Yamada, Masataka Sata and Koichi Node
    Citation: Cardiovascular Diabetology 2021 20:186
    Content type: Original investigation Published on:

  30. Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome with sex-specific pathophysiology. Estrogen deficiency is believed to be responsible for the development of HFpEF in women. Ho...

    Authors: Ke Shi, Meng-Xi Yang, Shan Huang, Wei-Feng Yan, Wen-Lei Qian, Yuan Li, Ying-Kun Guo and Zhi-Gang Yang
    Citation: Cardiovascular Diabetology 2021 20:185
    Content type: Original investigation Published on:

  31. Authors: Federico Biscetti, Giovanni Tinelli, Maria Margherita Rando, Elisabetta Nardella, Andrea Leonardo Cecchini, Flavia Angelini, Giuseppe Straface, Marco Filipponi, Vincenzo Arena, Dario Pitocco, Antonio Gasbarrini, Massimo Massetti and Andrea Flex
    Citation: Cardiovascular Diabetology 2021 20:184
    Content type: Correction Published on:

    The original article was published in Cardiovascular Diabetology 2021 20:114

  32. Insulin resistance is associated with the incidence of diabetes and cardiovascular diseases such as myocardial infarction. The ratio of triglycerides (TG) to high-density lipoprotein cholesterol (HDL-C) (TG/HD...

    Authors: Joungyoun Kim, Sang-Jun Shin, Ye-Seul Kim and Hee-Taik Kang
    Citation: Cardiovascular Diabetology 2021 20:183
    Content type: Original investigation Published on:

  33. Basement membrane (BM) accumulation is a hallmark of micro-vessel disease in diabetes mellitus (DM). We previously reported marked upregulation of BM components in internal thoracic arteries (ITAs) from type 2...

    Authors: Lasse Bach Steffensen, Xenia Emilie Sinding Iversen, Rasmus Søgaard Hansen, Pia Søndergaard Jensen, Anne-Sofie Faarvang Thorsen, Jes Sanddal Lindholt, Lars Peter Schødt Riber, Hans Christian Beck and Lars Melholt Rasmussen
    Citation: Cardiovascular Diabetology 2021 20:182
    Content type: Original investigation Published on:

  34. Recent treatment guidelines support the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes and cardiovascular disease based on the results of cardiovascular outcome tria...

    Authors: Lisanne C. A. Smidt, Frank L. J. Visseren, Wendela L. de Ranitz-Greven, Hendrik M. Nathoe, L. Jaap Kappelle, Gert J. de Borst, Harold W. de Valk and Jan Westerink
    Citation: Cardiovascular Diabetology 2021 20:181
    Content type: Original investigation Published on:

  35. Patients with diabetes mellitus (DM) have a higher prevalence of heart failure (HF) than those without it. Approximately 40 % of HF patients have DM and they tend to have poorer outcomes than those without DM....

    Authors: Se Yong Jang, Jieun Jang, Dong Heon Yang, Hyun-Jai Cho, Soo Lim, Eun-Seok Jeon, Sang Eun Lee, Jae-Joong Kim, Seok-Min Kang, Sang Hong Baek, Myeong-Chan Cho, Dong-Ju Choi, Byung-Su Yoo, Kye Hun Kim, Sue K. Park and Hae-Young Lee
    Citation: Cardiovascular Diabetology 2021 20:180
    Content type: Original investigation Published on:

  36. Type 2 diabetes mellitus is common in patients undergoing dialysis. However, the association between anti-diabetic drug use and survival outcomes is rarely discussed. We aimed to investigate whether continued ...

    Authors: Shih-Hsiang Ou, Hsin-Yu Chen, Nai-Wen Fang, Chun-Hao Yin, Chien-Liang Chen and Jin-Shuen Chen
    Citation: Cardiovascular Diabetology 2021 20:179
    Content type: Original investigation Published on:

  37. Type 2 diabetes causes cardio-renal complications and is treated with different combination therapies. The renal hemodynamics profile of such combination therapies has not been evaluated in detail.

    Authors: Christian Ott, Susanne Jung, Manuel Korn, Dennis Kannenkeril, Agnes Bosch, Julie Kolwelter, Kristina Striepe, Peter Bramlage, Mario Schiffer and Roland E. Schmieder
    Citation: Cardiovascular Diabetology 2021 20:178
    Content type: Original investigation Published on:

  39. It remains uncertain if prior use of oral anticoagulants (OACs) in COVID-19 outpatients with multimorbidity impacts prognosis, especially if cardiometabolic diseases are present. Clinical outcomes 30-days afte...

    Authors: José Miguel Rivera-Caravaca, Stephanie L. Harrison, Benjamin J. R. Buckley, Elnara Fazio-Eynullayeva, Paula Underhill, Francisco Marín and Gregory Y. H. Lip
    Citation: Cardiovascular Diabetology 2021 20:176
    Content type: Original investigation Published on:

  40. Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of a deterioration in heart failure (HF) and mortality in patients with a broad range of cardiovascular risks. Recent guidelines recommend cons...

    Authors: Atsushi Tanaka, Shigeru Toyoda, Takumi Imai, Kazuki Shiina, Hirofumi Tomiyama, Yasushi Matsuzawa, Takahiro Okumura, Yumiko Kanzaki, Katsuya Onishi, Arihiro Kiyosue, Masami Nishino, Yasushi Sakata and Koichi Node
    Citation: Cardiovascular Diabetology 2021 20:175
    Content type: Original investigation Published on:

  41. Although both a history of cerebrovascular disease (CVD) and glucose abnormality are risk factors for CVD, few large studies have examined their association with subsequent CVD in the same cohort. Thus, we com...

    Authors: Momoko Oe, Kazuya Fujihara, Mayuko Harada-Yamada, Taeko Osawa, Masaru Kitazawa, Yasuhiro Matsubayashi, Takaaki Sato, Yuta Yaguchi, Midori Iwanaga, Hiroyasu Seida, Takaho Yamada and Hirohito Sone
    Citation: Cardiovascular Diabetology 2021 20:174
    Content type: Original investigation Published on:

  42. There is a high incidence of cardiovascular disease in diabetes. Weight variability has been reported as independent risk factor for cardiovascular disease in the general population and preliminarily also in p...

    Authors: Antonio Ceriello, Giuseppe Lucisano, Francesco Prattichizzo, Björn Eliasson, Stefan Franzén, Ann-Marie Svensson and Antonio Nicolucci
    Citation: Cardiovascular Diabetology 2021 20:173
    Content type: Original investigation Published on:

  43. Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-induced infection, the cause of coronavirus disease 2019 (COVID-19), is characterized by acute clinical pathologies, including various coagulopathie...

    Authors: Etheresia Pretorius, Mare Vlok, Chantelle Venter, Johannes A. Bezuidenhout, Gert Jacobus Laubscher, Janami Steenkamp and Douglas B. Kell
    Citation: Cardiovascular Diabetology 2021 20:172
    Content type: Original investigation Published on:

  44. Risk stratification of patients with prediabetes is an unmet clinical need. Here, we examine the utility of subclinical myocardial necrosis assessed by high-sensitivity cardiac troponin T (hs-cTnT) in predicti...

    Authors: Marco Witkowski, Yuping Wu, Stanley L. Hazen and W. H. Wilson Tang
    Citation: Cardiovascular Diabetology 2021 20:171
    Content type: Original investigation Published on:

  46. Randomized controlled trials showed that sodium/glucose cotransporter-2 inhibitors (SGLT2i) protect the heart and kidney in an array of populations with type 2 diabetes (T2D) and increased cardiorenal risk. Ho...

    Authors: Meir Schechter, Cheli Melzer-Cohen, Aliza Rozenberg, Ilan Yanuv, Gabriel Chodick, Avraham Karasik, Mikhail Kosiborod and Ofri Mosenzon
    Citation: Cardiovascular Diabetology 2021 20:169
    Content type: Original investigation Published on:

  47. Compared to individuals without type 2 diabetes mellitus, the relative increase in cardiovascular mortality is much higher in women than in men in individuals with type 2 diabetes mellitus.

    Authors: Marcello Ricardo Paulista Markus, Till Ittermann, Sabine Schipf, Martin Bahls, Matthias Nauck, Henry Völzke, Raul Dias Santos, Annette Peters, Tanja Zeller, Stephan Burkhard Felix, Ramachandran S. Vasan, Barbara Thorand, Elisabeth Steinhagen-Thiessen and Marcus Dörr
    Citation: Cardiovascular Diabetology 2021 20:168
    Content type: Original investigation Published on:

  48. There is a controversy over the association between obesity and the risk of renal events in patients with type 2 diabetes mellitus (T2DM). Furthermore, whether body weight (BW) loss following sodium glucose co...

    Authors: Yi-Hsin Chan, Shao-Wei Chen, Tze-Fan Chao, Yi-Wei Kao, Chien-Ying Huang and Pao-Hsien Chu
    Citation: Cardiovascular Diabetology 2021 20:167
    Content type: Original investigation Published on:

  49. Nesfatin-1, a novel adipokine and dipeptidyl peptidase-4 (DPP4), a mam malian serine protease, are potent factors of atherosclerosis. In the present cross-sectional study, we investigated whether the plasma ne...

    Authors: Nikolaos P. E. Kadoglou, Emmanouil Korakas, Stylianos Lampropoulos, Eirini Maratou, George Kassimis, Nikolaos Patsourakos, Panagiotis Plotas, Paraskevi Moutsatsou and Vaia Lambadiari
    Citation: Cardiovascular Diabetology 2021 20:166
    Content type: Original investigation Published on:

  50. COVID-19 diabetic adults are at increased risk of severe forms irrespective of obesity. In patients with type-II diabetes, fat distribution is characterized by visceral and ectopic adipose tissues expansion, r...

    Authors: Franck Phan, Samia Boussouar, Olivier Lucidarme, Mohamed Zarai, Joe-Elie Salem, Nadjia Kachenoura, Khaoula Bouazizi, Etienne Charpentier, Yasmine Niati, Hasnae Bekkaoui, Zahir Amoura, Alexis Mathian, Olivier Benveniste, Patrice Cacoub, Yves Allenbach, David Saadoun…
    Citation: Cardiovascular Diabetology 2021 20:165
    Content type: Original investigation Published on:
journal logo

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Submit manuscript

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 8.5
    5-year Journal Impact Factor: 8.9
    Source Normalized Impact per Paper (SNIP): 1.855
    SCImago Journal Rank (SJR): 2.621

    Speed 2023
    Submission to first editorial decision (median days): 2
    Submission to acceptance (median days): 56

    Usage 2023
    Downloads: 2,523,778
    Altmetric mentions: 3,115

Cardiovascular Diabetology

ISSN: 1475-2840